EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring Radiographic Progression-Free Survival in Diverse Subgroups of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Efficacy of Abiraterone and Enzalutamide

Aykut Özmen iD, Deniz Tural

Journal of Clinical Medicine · 27.06.2026 · 15 (13) · 5012

DOI: 10.3390/jcm15135012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.06.2026. Verfasst von Aykut Özmen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Başakşehir Çam and Sakura City Hospital, Istanbul 34480, Turkey. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Metastatic hormone-sensitive prostate cancer (mHSPC) is a biologically heterogeneous disease in which treatment intensification with androgen receptor pathway inhibitors has significantly improved clinical outcomes. However, direct comparative evidence between abiraterone and enzalutamide remains limited. We aimed to evaluate radiographic progression-free survival (rPFS) in patients with mHSPC treated with first-line abiraterone or enzalutamide and to perform exploratory subgroup analyses according to baseline clinical and laboratory characteristics.

Methods

This retrospective single-center study included patients with mHSPC who received first-line abiraterone or enzalutamide in combination with androgen deprivation therapy. Baseline demographic, clinical, and laboratory characteristics were collected retrospectively. The primary endpoint was rPFS. Survival was analyzed using the Kaplan–Meier method and compared using the log-rank test.

Results

A total of 172 patients were included, of whom 84 received abiraterone and 88 received enzalutamide. The median follow-up duration was 24.7 months (95% CI 21.5–27.9). In the overall population, median rPFS was comparable between the abiraterone and enzalutamide groups (50 vs. 49 months, p = 0.21). However, enzalutamide was associated with significantly longer rPFS among patients aged

Schlagwörter

Stichwörter der Autor:innen

abirateroneandrogen receptor pathway inhibitorsenzalutamidemetastatic hormone-sensitive prostate cancerradiographic progression-free survivalreal-world studysubgroup analysis

Autor:innen und Institutionen

  • Department of Medical Oncology, Başakşehir Çam and Sakura City Hospital, Istanbul 34480, Turkey.
  • Department of Medical Oncology, Koç University Hospital, Istanbul 34010, Turkey.

ORCID-Profile: Aykut Özmen

Zitieren

APA

Özmen, A., & Tural, D. (2026). Exploring Radiographic Progression-Free Survival in Diverse Subgroups of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Efficacy of Abiraterone and Enzalutamide. Journal of Clinical Medicine, 15(13), 5012. https://doi.org/10.3390/jcm15135012

Vancouver

Özmen A, Tural D. Exploring Radiographic Progression-Free Survival in Diverse Subgroups of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Efficacy of Abiraterone and Enzalutamide. Journal of Clinical Medicine. 2026;15(13):5012. doi:10.3390/jcm15135012

BibTeX
@article{zmen2026,
  author = {Özmen, Aykut and Tural, Deniz},
  title = {Exploring Radiographic Progression-Free Survival in Diverse Subgroups of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Efficacy of Abiraterone and Enzalutamide},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {5012},
  doi = {10.3390/jcm15135012}
}
Kostenlos starten →